How does PLUR's PB Ratio compare to its peers?

PLUR is expensive based on its Price-To-Book Ratio (6.8x) compared to the peer average (4.2x).

How does PLUR's PB Ratio compare vs other companies in the Asian Biotechs Industry?

PLUR is expensive based on its Price-To-Book Ratio (6.8x) compared to the Asian Biotechs industry average (3x).

What is PLUR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate PLUR's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of PLUR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate PLUR's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Pluri (TASE:PLUR) - Stock Price, News & Analysis

PLUR Stock Overview

A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. More details

PLUR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 0.3% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($357K)

Highly volatile share price over the past 3 months

Does not have a meaningful market cap (₪31M)

Shareholders have been diluted in the past year

Pluri Inc. Competitors

Evogene

TASE:EVGN

₪35.0m

Grace Breeding

TASE:GRAC

₪67.9m

G.F.C Green Fields Capital

TASE:GFC-M

₪115.4m

Bonus BioGroup

TASE:BONS

₪136.6m

Price History & Performance

Summary of all time highs, changes and price drops for Pluri
Historical stock prices
Current Share Price	US$21.19
52 Week High	US$30.71
52 Week Low	US$15.04
Beta	1.45
11 Month Change	-6.50%
3 Month Change	19.91%
1 Year Change	-24.13%
33 Year Change	-83.40%
5 Year Change	-87.73%
Change since IPO	-97.10%

Recent updates

Shareholder Returns

	PLUR	IL Biotechs	IL Market
7D	-26.3%	-2.1%	1.0%
1Y	-24.1%	-6.8%	26.0%

Return vs Industry: PLUR underperformed the IL Biotechs industry which returned 14.9% over the past year.

Return vs Market: PLUR underperformed the IL Market which returned 14.6% over the past year.

Price Volatility

Is PLUR's price volatile compared to industry and market?
PLUR volatility
PLUR Average Weekly Movement	11.0%
Biotechs Industry Average Movement	4.8%
Market Average Movement	4.0%
10% most volatile stocks in IL Market	7.2%
10% least volatile stocks in IL Market	2.9%

Stable Share Price: PLUR's share price has been volatile over the past 3 months.

Volatility Over Time: PLUR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of IL stocks.

About the Company

Founded	Employees	CEO	Website
2001	129	Yaky Yanay	www.pluri-biotech.com

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company’s development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications.

Pluri Inc. Fundamentals Summary

How do Pluri's earnings and revenue compare to its market cap?
PLUR fundamental statistics
Market cap	₪115.18m
Earnings (TTM)	-₪88.98m
Revenue (TTM)	₪1.33m

83.9x

P/S Ratio

-1.3x

P/E Ratio

Is PLUR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PLUR income statement (TTM)
Revenue	US$357.00k
Cost of Revenue	US$9.00k
Gross Profit	US$348.00k
Other Expenses	US$24.30m
Earnings	-US$23.95m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.60
Gross Margin	97.48%
Net Profit Margin	-6,708.40%
Debt/Equity Ratio	368.8%

How did PLUR perform over the long term?

See historical performance and comparison

PLUR Stock Overview

Rewards

Risk Analysis

Pluri Inc. Competitors

TASE:EVGN

₪35.0m

TASE:GRAC

₪67.9m

TASE:GFC-M

₪115.4m

TASE:BONS

₪136.6m

Price History & Performance

Recent News & Updates

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Recent updates

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)

New minor risk - Share price stability

Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023)

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022)

Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

Pluri Inc. announced that it has received $8.469323 million in funding

Pluri Inc. announced that it expects to receive $8.170972 million in funding

High number of new and inexperienced directors

Pluri Receives Non-Compliance Letter from Nasdaq

Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem Therapeutics Inc. Announces Board Changes

High number of new directors

High number of new directors

Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture

High number of new directors

Chairman recently bought ₪467k worth of stock

Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Independent Director Isaac Braun has left the company

Insider recently sold ₪5.1m worth of stock

Insider recently sold ₪330k worth of stock

Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans

New 90-day low: ₪17.40

Revenue in line with expectations

Pluristem Therapeutics Inc. Announces Board Appointments

Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico

Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

New 90-day low: ₪24.00

Insider recently bought ₪641k worth of stock

Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study

New 90-day low: ₪28.82

Revenue in line with expectations

Insider recently bought ₪629k worth of stock

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

Insider recently bought ₪1.1m worth of stock

Full year earnings released - ₪1.60 loss per share

New 90-day high - ₪36.37

Shareholder Returns

Price Volatility

About the Company

Pluri Inc. Fundamentals Summary

83.9x

-1.3x

Earnings & Revenue